Oramed Pharmaceuticals Inc. — Director's Dealing 2026

Jan 22, 2026

{0}------------------------------------------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:	0.5

	Check this box to indicate that atransaction was made pursuant to acontract, instruction or written planfor the purchase or sale of equitysecurities of the issuer that isintended to satisfy the affirmativedefense conditions of Rule 10b5-1(c). See Instruction 10.
--	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Instruction 1(b).

	1(c). See Instruction 10.
1. Name and Address of Reporting Person*Kidron Miriam				2. Issuer Name and Ticker or Trading SymbolORAMED PHARMACEUTICALS INC.[									5. Relationship of Reporting Person(s) to Issuer(Check all applicable)
				ORMP ]									Director			10% Owner
(Last)	(First)(Middle)														below)	Officer (give title		Other (specifybelow)
FLOOR		1185 AVENUE OF THE AMERICAS, THIRD				01/14/2026					3. Date of Earliest Transaction (Month/Day/Year)					Chief Scientific Officer
											4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Individual or Joint/Group Filing (Check Applicable
(Street)NEW YORK	NY		10036											Line)		Form filed by One Reporting PersonForm filed by More than One Reporting
(City)		(State)	(Zip)												Person
											Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)2. TransactionDate(Month/Day/Year)				if any		2A. DeemedExecution Date,(Month/Day/Year)		3.TransactionCode (Instr.5)8)			4. Securities Acquired (A) orDisposed Of (D) (Instr. 3, 4 and			SecuritiesBeneficially	5. Amount ofOwned Following	6. OwnershipForm: Direct(D) or Indirect(I) (Instr. 4)		7. Natureof IndirectBeneficialOwnership
									Code	V	Amount	(D)	(A) or	Price	Reported	Transaction(s)(Instr. 3 and 4)			(Instr. 4)
Common Stock01/14/2026								(1)G		86,166	D		$0		1,343,498		D
											Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned(e.g., puts, calls, warrants, options, convertible securities)
1. Title of2.DerivativeConversionSecurityor Exercise(Instr. 3)Price ofDerivativeSecurity		3. TransactionDate(Month/Day/Year)	3A. DeemedExecution Date,if any(Month/Day/Year)		4.TransactionCode (Instr.8)		5. NumberofDerivativeSecuritiesAcquired(A) orDisposedof (D)(Instr. 3, 4and 5)		Expiration Date(Month/Day/Year)		6. Date Exercisable and	7. Title andAmount ofSecuritiesUnderlyingDerivativeSecurity (Instr.3 and 4)		Amount	8. Price ofDerivativeSecurity(Instr. 5)	9. Number ofderivativeSecuritiesBeneficiallyOwnedFollowingReportedTransaction(s)(Instr. 4)	10.	OwnershipForm:Direct (D)or Indirect(I) (Instr. 4)	11. Natureof IndirectBeneficialOwnership(Instr. 4)
									Date		Expiration		orof	Number

Explanation of Responses:

1. This transaction represents a charitable donation and is not a market transaction, thus no price has been reported. No value was received for the donated shares. The Reporting Person is not affiliated with, and has no control over, the donee.

Exercisable

Code V (A) (D)

/s/ Miriam Kidron 01/21/2026

Date Title

** Signature of Reporting Person Date

Shares

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

• * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
• ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.